Navigation Links
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Date:8/20/2007

Analysis published in the journal Blood found 92 percent reduction in

incidence of thromboses

CHESHIRE, Conn., Aug. 20 /PRNewswire-FirstCall/ -- Patients with a rare blood disorder called PNH experienced a 92 percent reduction in the incidence of life-threatening blood clots (thromboses) following treatment with Soliris(TM) (eculizumab), according to an analysis of clinical studies recently published online in Blood, the journal of the American Society of Hematology.

Soliris, developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), is the first therapy approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare, debilitating and life-threatening blood disorder defined by the destruction of red blood cells, or hemolysis. In patients with PNH, hemolysis can cause severe anemia, disabling fatigue, recurrent pain, shortness of breath, pulmonary hypertension, intermittent episodes of dark colored urine (hemoglobinuria), kidney disease, impaired quality of life and thromboses. (1,2)

"Thrombosis is the leading cause of premature death in PNH patients and the most feared complication of PNH," said Dr. Peter Hillmen, senior author of the paper and Consultant Haematologist of the General Infirmary at Leeds, Leeds, UK. "In several clinical trials, Soliris reduced hemolysis in all PNH patients and significantly improved anemia, fatigue and quality of life. The comprehensive analyses demonstrate that Soliris substantially reduced the risk of thrombosis in a diverse population of PNH patients, including those who might be expected to have less severe disease."

Approximately 40 percent of patients with PNH experience thrombosis during the course of the disease.(3,4,5,6) An ini
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sensitive detection of tumor cells in peripheral blood of carcinoma patients by a reverse transcription PCR method
2. Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A
3. What patients want: A story of choice, clinical trials & evidence-based medicine
4. Heart patients benefit from digital image network
5. LEDS Bring Relief to Young Cancer Patients
6. CPM Helps Physicians Group Retain Patients with New Kind of House Call
7. Fast and Easy Isolation of PCR-Ready Genomic DNA from Whole Blood
8. Genomic DNA Extraction from Buccal Swabs Using the Perfect gDNA Blood Mini Kit
9. Genomic DNA Extraction from Buffy Coat Using the Perfect gDNA Blood Mini Kit
10. EppendorfPerfect gDNA Blood Mini Kit
11. Higher gDNA Concentrations with the Perfect gDNA Blood Mini Kit by Varying the Final Elution Volume
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a significant ... Inc. in excess of $10 million. The jury determined ... and that it improperly hired one or more of ... for judgment notwithstanding the verdict, a new trial, and ...
(Date:2/26/2015)... --  Synageva BioPharma Corp. (NASDAQ: ... for rare disorders, today reported 2014 full year ... objectives, and financial guidance.  Synageva,s management team will ... EST to review the financial results and provide ... call by telephone, please dial (877) 445-4603 for ...
(Date:2/26/2015)... FT. LAUDERDALE, Fla. , Feb. 26, 2015 /PRNewswire/ ... discussed growth priorities driven by key research advancements ... Health segments at today,s Bank of America Merrill Lynch ... worldwide met the challenge of building grain supplies the ... expected to continue at the pace of the last ...
(Date:2/26/2015)... , Feb. 26, 2015  NuGene International, Inc. ... products for skin and hair rejuvenation, has announced ... agency of record for investor relations and strategic ... our distribution, sales and diversification strategies – and ... and prospective shareholders," stated Ali Kharazmi CEO of ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... 4, 2012 Luminex Corporation (NASDAQ: LMNX) today announced ... Morgan Healthcare Conference to be held January 9 -12, ... http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) The investor presentation by Patrick ... at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) on ...
... Jan. 4, 2012  Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today ... will be presenting at JP Morgan,s 30th Annual Healthcare ... Mr. Bentsur,s presentation is scheduled to take place on ... ET).  A live audio webcast of Mr. ...
... InterMune, Inc. (NASDAQ: ITMN) today announced that it ... sales of Esbriet® (pirfenidone) in Germany, as well as ... the open of the U.S. markets on Thursday, January ... be hosted by InterMune at 8:30 a.m. Eastern time ...
Cached Biology Technology:Luminex Corporation to Present at JP Morgan Healthcare Conference 2Keryx Biopharmaceuticals to Present at JP Morgan's 30th Annual Healthcare Conference 2InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5 2
(Date:2/18/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that its ... investors to participate via webcast. , Cowen and Company ... March 3, 2015 at 11.20 a.m. Eastern Time , ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... for these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62/113114 for DISTRIBUTED METHOD ... The patent further establishes NXT-ID,s position in ... intellectual property portfolio the ability for multiple devices to ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... experts on biodiversity will gather from the 21th to the ... the transfer of biodiversity knowledge from the scientific community into ... in a project funded by the European Commission: " BiodiversityKnowledge ... practitioners to help all actors in the field of biodiversity ...
... Exercise clears the mind. It gets the blood pumping ... is familiar territory, but Dartmouth,s David Bucci thinks there ... several years there have been data suggesting that neurobiological ... work here," says Bucci, an associate professor in the ...
... Scientists at Queen Mary, University of London have ... underlying causes of psychiatric disorders. The study, published ... found zebrafish can modify their behaviour in response to ... School of Biological and Chemical Sciences who led the ...
Cached Biology News:A network of knowledge on biodiversity and ecosystem services in Europe 2Dartmouth researchers are learning how exercise affects the brain 2Dartmouth researchers are learning how exercise affects the brain 3Zebrafish could hold the key to understanding psychiatric disorders 2
... polystyrene with frosted labeling surfaces, volume ... counting. 100% integrity tested. Linkage: This ... number, created to easily match Cornings ... yet, please order under the old ...
Automated Cell Culture Flask...
... system, 100-240 V, uses multiplex suspension array ... of up to 100 proteins and peptides ... array is composed of up to 100 ... be conjugated with a unique reactant specific ...
...
Biology Products: